Systolic and diastolic blood pressure control in antihypertensive drug trials

Journal of Hypertension

Volumn 20, Issue 8, 2002, Pages 1461-1464

  Mancia, Giuseppe ^a,b   Grassi, Guido ^a,b  

^a SAN GERARDO HOSPITAL   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CLINICAL PRACTICE; DIASTOLIC BLOOD PRESSURE; DOCTOR PATIENT RELATION; DRUG EFFECT; DRUG RESPONSE; EDITORIAL; EXPERT SYSTEM; GENERAL PRACTICE; HUMAN; HYPERTENSION; MONOTHERAPY; MOTIVATION; PATIENT COMPLIANCE; PATIENT EDUCATION; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; BLOOD PRESSURE; CLINICAL TRIAL; PATHOPHYSIOLOGY; PRACTICE GUIDELINE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CLINICAL TRIALS; HUMANS; HYPERTENSION; PATIENT COMPLIANCE; PRACTICE GUIDELINES;

EID: 0036668188     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200208000-00001     Document Type: Editorial

References (35)

1. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure
2. 1999 World Health Organization/International Society of Hypertension Guidelines for the management of hypertension
3. A practical approach to achieving recommended blood pressure goals in diabetic patients
4. Hypertension in chronic renal failure
5. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: Principal results from EUROASPIRE II Euro Heart Survey Programme
6. Current standard of care in patients affected by coronary heart disease in Italy: The MC '95 study
7. The challenge of controlling systolic blood pressure: Data from the National Health and Nutrition Examination Survey (NHANES III), 1988-1994
8. Systolic versus diastolic blood pressure control in the hypertensive patients of the PAMELA population
9. Systolic versus diastolic blood pressure and risk of coronary heart disease: Framingham Study
10. The role of systolic blood pressure in determining risk for cardiovascular diseases
11. Patient non-compliance with drug regimens: Measurement, clinical correlates, economic impact
12. Contribution of fixed low-dose combinations to initial therapy in hypertension
13. Randomized trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) Study
14. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)
15. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial
16. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomized trial
17. Randomized trial of a perindopril-based blood pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack
18. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
19. Randomized trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and mobidity in the Swedish Trial in Old Patients with Hypertension-2 study
20. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
21. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
22. Shanghai trial of nifedipine in the elderly (STONE)
23. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICROHOPE substudy
24. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
25. Outcomes results of the Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET) in patients with hypertension and NIDDM
26. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension
27. Influence of diabetics and type of hypertension on response to antihypertensive treatment
28. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type-2 diabetes
29. Effects of losartan on renal and cardiovascular outcomes in patients with type-2 diabetes and nephropathy
30. The effect of irbesartan on the development of diabetic nephropathy in patients with type-2 diabetes
31. Reduced CV morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen. A subanalysis of the Captopril Prevention Project
32. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
33. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: Results from the Swedish Trial in Old Patients with Hypertension-2
34. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study
35. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial on cardiovascular events in hypertension: Rationale and design